Sanofi acquires 4.9% of Novavax shares for $70 million, doubling the latter's valuation to around $1.4 billion. This investment is part of a co-exclusive licensing agreement...
As vaccine sales for Novavax, Moderna, and BioNTech shift in line with a changing Covid-19 situation, the results are being felt in the stock markets. Here...